PAP
CTNM

Persistent Asset Partners’s Contineum Therapeutics CTNM Stock Holding History

Persistent Asset Partners’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$541K Buy
+33,037
New +$433K 0.16% 104
2026
Q1 		– Sell
-13,853
Closed -$158K – 495
2025
Q4 		$158K Buy
+13,853
New +$158K 0.07% 240

Other funds holding CTNM

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Persistent Asset Partners's CTNM Position: Q2 2026 in Review

Persistent Asset Partners opened a new position in Contineum Therapeutics (CTNM) in Q2 2026: 33,037 shares worth $541K. The stake represents 0.16% of the portfolio and ranks #104 among its holdings. This is a return to the name: Persistent Asset Partners previously reported a position in CTNM as recently as Q4 2025.

Persistent Asset Partners first reported a position in CTNM in Q4 2025 and has held it in 2 quarters since. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • Persistent Asset Partners held 33,037 shares of Contineum Therapeutics worth $541K as of Q2 2026.
  • Contineum Therapeutics was a new Persistent Asset Partners position in Q2 2026.
  • Contineum Therapeutics made up 0.16% of Persistent Asset Partners's portfolio in Q2 2026, its #104 holding.
  • Persistent Asset Partners first reported a position in Contineum Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.